Intra-Cellular Therapies (ITCI) Baird's 2024 Global Healthcare Conference summary

Company overview and product highlights

• Founded in 2002, leveraging Nobel Prize-winning research on intracellular signaling pathways in the brain.

• Developed CNSProfile platform to analyze brain pathways and guide drug development.

• CAPLYTA (lumateperone) approved for schizophrenia (2019) and bipolar depression (2021), with strong market growth.

• 2023 revenues for CAPLYTA reached $462 million, with 2024 guidance of $650–$680 million.

• Expanding sales force to target more primary care providers, especially for bipolar disorder and anticipated MDD approval.

Product differentiation and market strategy

• CAPLYTA is considered best-in-class for efficacy, safety, and tolerability among antipsychotics.

• No dose titration required; therapeutic dose achieved with first administration.

• Broadest label in its class, covering Bipolar I, Bipolar II (adjunctive and monotherapy), and schizophrenia.

• Minimal metabolic side effects and no movement disturbances, differentiating it from competitors.

• Broad payer coverage, with over 99% in Medicare/Medicaid and over 90% in commercial plans.

Pipeline and development programs

• Large pediatric program for lumateperone targeting bipolar disorder and autism-related irritability.

• 1284 (deuterated lumateperone) in phase II for generalized anxiety disorder and Alzheimer’s-related indications; studies powered for registration.

• PDE1 inhibitor (214) in phase II for Parkinson’s disease, focusing on movement disturbances, cognition, and neuroinflammation.

• 333 (mu-opioid partial agonist) in trials for substance use disorder and pain; progressing through PET and dose studies.

• 1549 (neuroplastogen platform) aims to deliver non-hallucinogenic psychedelics for rapid-onset depression treatment, entering clinic next year.